<DOC>
	<DOCNO>NCT01246960</DOCNO>
	<brief_summary>The purpose study determine whether ramucirumab use conjunction chemotherapy treatment help participant stomach , esophagus , gastroesophageal cancer .</brief_summary>
	<brief_title>A Study Ramucirumab Participants With Gastric , Esophageal , Gastroesophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologic cytologic confirmation adenocarcinoma esophagus , gastroesophageal junction ( GEJ ) , stomach Metastatic locally advance , unresectable disease time study entry Provided sign informed consent amenable compliance protocol schedule test Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 01 study entry Adequate renal , hematological , hepatic function Measurable nonmeasurable disease time study entry Resolution Grade less equal 1 National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) , Version 4.0 , clinically significant toxic effect prior locoregional therapy , surgery , anticancer therapy , except otherwise mention eligibility criterion Eligible participant reproductive potential ( sex ) must agree use adequate contraceptive method ( hormonal barrier method ) study period least 12 week last dose study therapy Life expectancy great equal 3 month Willingness provide blood tissue sample research purpose . Submission tumor specimen mandatory participation study , histologic , paraffinembedded specimen exists ( either surgical resection biopsy ) ; submission paraffin block minimum 8 unstained slide require sufficient sample . NOTE : If insufficient additional tissue exists ( , tissue utilized prior diagnostic purpose ) , participation study allowable without requirement additional biopsy ; situation must discuss study principal investigator and/or ImClone medical monitor designee . The participant receive prior firstline systemic therapy advanced/unresectable and/or metastatic disease ( prior adjuvant neoadjuvant therapy permit ) Previous concurrent malignancy except basal squamous cell skin cancer and/or situ carcinoma cervix , solid tumor treat curatively without evidence recurrence least 3 year prior study entry Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator would make participant ineligible entry study The participant receive chronic therapy nonsteroidal antiinflammatory agent ( NSAIDs ; example , indomethacin , ibuprofen , naproxen , similar agent ) antiplatelet agent ( example , clopidogrel , ticlopidine , dipyridamole , anagrelide ) . Aspirin use dose 325 milligram per day ( mg/day ) permit . The participant significant thirdspace fluid retention ( example , ascites pleural effusion ) , amenable require repeat drainage The participant pregnant breastfeeding Uncontrolled intercurrent illness include , limited , active uncontrolled clinically serious infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , uncontrolled thromboembolic , hemorrhagic disorder , psychiatric illness/social situation , comorbid systemic illness , severe concurrent disease Immunocompromised participant include participant know human immunodeficiency virus ( HIV ) positive . Progressive disease less equal 12 month complete platinum 5FU treatment , include capecitabine , give previously perioperative ( adjuvant neoadjuvant ) set Current recent ( within 28 day prior randomization ) treatment investigational drug receive regulatory approval indication time study entry , participation another interventional clinical trial . Participants participate survey observational study eligible participate study . Are currently enrol , discontinue within last 28 day , clinical trial involve ramucirumab drug product ( DP ) , concurrently enrol type medical research judge scientifically medically compatible study Received prior therapy antiangiogenic agent ( include limit bevacizumab , sunitinib , sorafenib ) Major surgical procedure significant traumatic injury le 28 day prior randomization , anticipation need elective planned major surgical procedure course study . Subcutaneous venous access device placement within 7 day prior randomization Clinically significant peripheral neuropathy time registration Known central nervous system metastases symptomatic untreated New York Heart Association ( NYHA ) classification IIIIV congestive heart failure Greater normal risk bleed coagulopathy absence therapeutic anticoagulation ; Grade 3/4 gastrointestinal bleeding within 3 month prior registration ; active bleeding ( , within 14 day prior first dose study therapy ) ; pathological condition present carry high risk bleeding ( example , tumor involve major vessel know varix ) Participant experience arterial thromboembolic event , include limited myocardial infarction , stroke , transient ischemic attack ( TIA ) , cerebrovascular accident , unstable angina , less equal 6 month prior registration Clinically significant vascular disease ( example , aortic aneurysm , aortic dissection ) minimal intervention administer planned History hypertensive crisis hypertensive encephalopathy current poorlycontrolled hypertension despite standard medical management History abdominal fistula , gastrointestinal perforation , intraabdominal abscess le 6 month prior registration Known hypersensitivity treatment component modify FOLFOX6 ( mFOLFOX6 ) ( oxaliplatin , 5FU , leucovorin ) ramucirumab DP</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>cancer</keyword>
	<keyword>stomach</keyword>
	<keyword>esophagus</keyword>
	<keyword>gastroesophageal</keyword>
</DOC>